Loading clinical trials...
Loading clinical trials...
A Randomized, Double-blind, Placebo-controlled, Dose-ranging Pilot Study Evaluating the Efficacy and Safety of YM087 in Patients With Decompensated Chronic Heart Failure
This is a randomized, double-blind, placebo-controlled, dose ranging pilot study to examine the effects of conivaptan in patients with acute decompensated heart failure.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
The Heart Center, P.C.
Huntsville, Alabama, United States
LA County/USC Medical Center
Los Angeles, California, United States
San Joaquin Cardiology
Manteca, California, United States
Apex Research Institute
Santa Ana, California, United States
The Greater Fort Lauderdale Heart Group Research
Fort Lauderdale, Florida, United States
Jacksonville Center for Clinical Research
Jacksonville, Florida, United States
U. Miami, Jackson Mem'l Medical Center
Miami, Florida, United States
Discovery Medical Research Group
Ocala, Florida, United States
Rush-Presbyterian St. Luke's Medical Center
Chicago, Illinois, United States
Louisiana State University Medical Center School of Medicine
New Orleans, Louisiana, United States
Start Date
November 1, 2002
Primary Completion Date
March 1, 2004
Completion Date
March 1, 2004
Last Updated
May 2, 2014
170
ACTUAL participants
conivaptan
DRUG
placebo
DRUG
Lead Sponsor
Cumberland Pharmaceuticals
NCT06019169
NCT07325942
NCT05934565
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions